{"prompt": "['Approval must be obtained from the IRB/EC and regulatory authorities (as locally required)', 'before implementation of any changes, except for changes necessary to eliminate an', 'immediate hazard to patients or changes that involve logistical or administrative aspects only', '(e.g., change in Medical Monitor or contact information).', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '91 / Protocol MO40628, Version 12']['10.', 'REFERENCES', 'Andersson M, L\u00f3pez-Vega JM, Petit T et al. Efficacy and Safety of Pertuzumab and', 'Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET', 'Cohort 2 Final Results. Oncologist. 2017 Oct;22(10):1160-1168.', 'Bonifazi M, Franchi M, Rossi M et al. Long term survival of HER2-positive early breast', 'cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from', 'clinical practice. Breast. 2014 Oct;23(5):573-8.', \"Cameron D, Piccart-Gebhart MJ, Gelber RD et al. 11 years' follow-up of trastuzumab after\", 'adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the', 'HERceptin Adjuvant (HERA) trial. Lancet. 2017;389:1195-1205.', 'Cardoso F, Costa A, Senkus E et al. 3rd ESO-ESMO International Consensus Guidelines for', 'Advanced Breast Cancer (ABC : 3). Ann Oncol. 2017 Jan 1;28(1):16-33.', 'Carr JA, Havstad S, Zarbo RJ et al. The association of HER-2/neu amplification with breast', 'cancer recurrence. Arch Surg. 2000 Dec;135(12):1469-74.', 'Coates AS, Winer EP, Goldhirsch A et al. Tailoring therapies-improving the management of', 'early breast cancer: St Gallen International Expert Consensus on the Primary Therapy', 'of Early Breast Cancer 2015. Ann Oncol. 2015 Aug;26(8):1533-46.', 'Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of', 'humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing', 'metastatic breast cancer that has progressed after chemotherapy for metastatic', 'disease. J Clin Oncol 1999;17:2639-2648,', 'Curigliano G, Burstein HJ, P Winer E et al. De-escalating and escalating treatments for', 'early-stage breast cancer: the St. Gallen International Expert Consensus Conference', 'on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017 Aug', ';28(8):1700-1712.', 'Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012 v1.0, Cancer Incidence and', 'Mortality Worldwide: IARC CancerBase No. 11 [Internet].Lyon, France: International', 'Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr,', 'accessed on 15/May/2015.', 'Franklin MC, Carey KD, Vajdos FF et al. Insights into ErbB signaling from the structure of', 'the ErbB2-pertuzumab complex. Cancer Cell 2004;5:317-28.', 'Gianni L, Eiermann W, Semiglazov V et al. Neoadjuvant chemotherapy with trastuzumab', 'followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients', 'with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised', 'controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010 Jan', '30;375(9712):377-84.', 'Gianni L, Pienkowski T, Im YH et al. Efficacy and safety of neoadjuvant pertuzumab and', 'trastuzumab in women with locally advanced, inflammatory, or early HER2-positive', 'breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.', 'Lancet Oncology 2012;13(1):25-32.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '92 / Protocol MO40628, Version 12']['Gianni L, Pienkowski T, Im YH et al. 5-Year analysis of neoadjuvant pertuzumab and', 'trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-', 'positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised', 'trial. Lancet Oncol 2016; 17(6): 791-800.', 'Gradishar WJ, Anderson BO, Aft R et al. NCCN clinical practice guidelines in oncology', '(NCCN Guidelines\u00ae). Breast Cancer. Version I.2018 [internet]. Available from:', ' https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.', 'Graus-Porta D, Beerli RR, Daly JM et al. ErbB-2, the preferred heterodimerization partner of', 'all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997 Apr 1; 16(7):', '1647-1655.', \"Herceptin Investigator's Brochure, v18, 2017\", 'Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers:', 'Overexpression and Therapeutic Implications. Mol Biol Int. 2014;2014:852748.', 'Ismael G, Hegg R, Muehlbauer S et al. Subcutaneous versus intravenous administration of', '(neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast', 'cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet', 'Oncol. 2012 Sep;13(9):869-78.', 'Jackisch C, Hegg R, Stroyakovskiy D et al. HannaH phase III randomised study: association', 'of total pathological complete response with event-free survival in HER2-positive early', 'breast cancer treated with neoadjuvant-adjuvan trastuzumab after 2 years of', 'treatment-free follow-up. Eur J Cancer 2016;62:62-75.', 'K\u00fcmmel S, Abraham J, Martin M et al. MetaPHER phase Illb multicenter, open-label, single-', 'arm safety study of subcutaneous trastuzumab in combination with pertuzumab and', 'docetaxel in patients with HER2-positive advanced breast cancer: First results.', 'Abstract P4-21-42.SABCS December 2016, San Antonio, USA.', 'Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in', 'human cancer pathogenesis. Oncogene. 2007 Oct 4;26(45):6469-87.', 'Molina MA, Codony-Servat J, Albanell J et al. Trastuzumab (herceptin), a humanized anti-', 'Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain', 'cleavage in breast cancer cells. Cancer Res. 2001 Jun 15;61(12):4744-9.', 'Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ', 'hybridization and correlation with immunohistochemistry in a cohort of 6556 breast', 'cancer tissues. Clin Breast Cancer. 2004 Apr;5(1):63-9.', 'Ozcelik C, Erdmann B, Pilz B et al. Conditional mutation of the ErbB2 (HER2) receptor in', 'cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A. 2002 Jun', '25;99(13):8880-5.', 'Pivot X, Gligorov J, M\u00fcller V et al. Preference for subcutaneous or intravenous', 'administration of trastuzumab in patients with HER2-positive early breast cancer', '(PrefHer): an open-label randomised study. Lancet Oncol 2013;14(10):962-70', \"Perjeta Investigator's Brochure, version 17, February 2018.\", 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '93 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}